| MEDICAL MARIJUANA |
| MAPS studies |
| Background |
| UMass Amherst Project |
| News |
| US research |
| International research |
| Additional resources |
|
| MAPS Membership |
| Psychedelic Art |
| Psychedelic Literature |
| MAPS Merchandise |
| Funding Priorities |
| MAPS SITE LINKS |
| GENERAL |
| Home Page |
| MAPS Store |
| Monthly News |
| Events Calendar |
| Contact MAPS |
| Links & Resources |
| RESEARCH |
| MDMA |
| Marijuana |
| Ibogaine |
| LSD/Psilocybin |
| Research Worldwide |
| INFO & MEDIA |
| MAPS in the Media |
| MAPS AV Archive |
| The MAPS Bulletin |
| Student Resources |
| Rites of Passage |
|
| < Return to MAPS / Orphan Drug Designation Main Page < Return to MAPS Main Medical Marijuana page |
| MAY 25 1999 - FDA Approval for MAPS' Request for Orphan Drug Designation for Smoked Marijuana in the Treatment of HIV-Associated Wasting Syndrome |
[CLICK FOR PDF VERSION]  |